Literature DB >> 342416

Mitogenic activity of bacterial lipopolysaccharides in vivo: morphological and functinal characterization of responding cells.

D L Peavy, R E Baughn, D M Musher.   

Abstract

The in vivo effect of bacterial lipopolysaccharides (LPS) on mouse spleen cell subpopulations was investigated. Intravenous administration of LPS resulted in marked enlargement of the spleen, accompanied by increased cellular proliferation and enhanced nucleated cell recoveries. At least two morphologically distinct cell types appeared to be targets for LPS. Polymorphonuclear leukocytes accumulated rapidly with a relatively minor degree of cell division. In contrast, a substantial proportion of splenic lymphocytes transformed into large lymphocytes and blast cells which actively incorporated [3H]thymidine. Proliferating cells were identified as bone marrow-derived (B) lymphocytes by their ability to form C3-dependent rosettes and to synthesize immunoglobulin. These cellular responses were not antigenically induced, since LPS derived from mutants lacking the polysaccharide moiety gave similar results. Thus, splenic B lymphocytes appear to interact and respond to LPS in vivo in the same manner as observed in vitro. These data suggest that the capacity of LPS to directly activate B lymphocytes, initiate cellular proliferation, and induce immunoglobulin production by bone marrow-derived cells in vivo may contribute to its adjuvant activity.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 342416      PMCID: PMC414050          DOI: 10.1128/iai.19.1.71-78.1978

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

1.  Induction of immunoglobulin and antibody synthesis in vitro by lipopolysaccharides.

Authors:  J Andersson; O Sjöberg; G Möller
Journal:  Eur J Immunol       Date:  1972-08       Impact factor: 5.532

2.  Mitogenicity of bacterial endotoxins: characterization of the mitogenic principle.

Authors:  D L Peavy; J W Shands; W H Adler; R T Smith
Journal:  J Immunol       Date:  1973-08       Impact factor: 5.422

3.  Synthesis, surface deposition and secretion of immunoglobulin M in bone marrow-derived lymphocytes before and after mitogenic stimulation.

Authors:  F Melchers; J Andersson
Journal:  Transplant Rev       Date:  1973

4.  Selective induction of DNA synthesis in T and B lymphocytes.

Authors:  J Andersson; G Möller; O Sjöberg
Journal:  Cell Immunol       Date:  1972-08       Impact factor: 4.868

5.  Cellular site of action of various adjuvants in antibody responses to hapten-carrier conjugates.

Authors:  T Hamaoka; D H Katz
Journal:  J Immunol       Date:  1973-11       Impact factor: 5.422

6.  Early cellular responses to mitogens and adjuvants in the mouse spleen.

Authors:  F Moatamed; M J Karnovsky; E R Unanue
Journal:  Lab Invest       Date:  1975-03       Impact factor: 5.662

7.  Immunologic properties of bacterial lipopolysaccharide (LPS). III. Genetic linkage between the in vitro mitogenic and in vivo adjuvant properties of LPS.

Authors:  B J Skidmore; J M Chiller; W O Weigle; R Riblet; J Watson
Journal:  J Exp Med       Date:  1976-01-01       Impact factor: 14.307

8.  Genetic control of responses to bacterial lipopolysaccharides in mice. I. Evidence for a single gene that influences mitogenic and immunogenic respones to lipopolysaccharides.

Authors:  J Watson; R Riblet
Journal:  J Exp Med       Date:  1974-11-01       Impact factor: 14.307

9.  The mitogenic effect of lipopolysaccharide on bone marrow-derived mouse lymphocytes. Lipid A as the mitogenic part of the molecule.

Authors:  J Andersson; F Melchers; C Galanos; O Lüderitz
Journal:  J Exp Med       Date:  1973-04-01       Impact factor: 14.307

10.  A population of lymphocytes bearing a membrane receptor for antigen-antibody-complement complexes. I. Separation and characterization.

Authors:  C Bianco; R Patrick; V Nussenzweig
Journal:  J Exp Med       Date:  1970-10-01       Impact factor: 14.307

View more
  11 in total

Review 1.  Polyclonal activators in pulmonary immune disease.

Authors:  W F Willoughby; J B Willoughby; G F Gerberick
Journal:  Clin Rev Allergy       Date:  1985-05

2.  Biological and immunological properties of Coxiella burnetii vaccines in C57BL/10ScN endotoxin-nonresponder mice.

Authors:  J C Williams; J L Cantrell
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

3.  Strain-dependent cytotoxic effects of endotoxin for mouse peritoneal macrophages.

Authors:  D L Peavy; R E Baughn; D M Musher
Journal:  Infect Immun       Date:  1978-07       Impact factor: 3.441

4.  Depression of the antibody response in Pseudomonas aeruginosa-injected mice.

Authors:  C Garzelli; V Colizzi; M Campa; L Bozzi; G Falcone
Journal:  Infect Immun       Date:  1979-04       Impact factor: 3.441

5.  Effects of BCG infection on the susceptibility of mouse macrophages to endotoxin.

Authors:  D L Peavy; R E Baughn; D M Musher; D M Musher
Journal:  Infect Immun       Date:  1979-04       Impact factor: 3.441

6.  Hypertriglyceridemic very low density lipoproteins induce triglyceride synthesis and accumulation in mouse peritoneal macrophages.

Authors:  S H Gianturco; W A Bradley; A M Gotto; J D Morrisett; D L Peavy
Journal:  J Clin Invest       Date:  1982-07       Impact factor: 14.808

7.  Evidence for lipid peroxidation in endotoxin-poisoned mice.

Authors:  D L Peavy; E J Fairchild
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

8.  A defined fragment of bacterial protein I (OmpF) is a polyclonal B-cell activator.

Authors:  M Vordermeier; K Stäb; W G Bessler
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

9.  Morphological and cytochemical characterization of cells infiltrating mouse lungs after influenza infection.

Authors:  P R Wyde; D L Peavy; T R Cate
Journal:  Infect Immun       Date:  1978-07       Impact factor: 3.441

10.  Polyclonal activation of B-lymphocytes in vivo by Salmonella typhimurium lipoprotein.

Authors:  R B Johnson; S Köhl; W G Bessler
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.